Gurcan Tunali

Gurcan Tunali

Auto-generated profile, based on publicly available information

Gurcan Tunali

Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DYDigdem Yoyen-Ermis
Digdem Yoyen-Ermis
GTGurcan Tunali
Gurcan Tunali
ETEce Tavukcuoglu
Ece Tavukcuoglu
UHUtku Horzum
Utku Horzum
DODidem Ozkazanc
Didem Ozkazanc
GEGunes Esendagli
Gunes Esendagli
Interferon (IFN)-γ is the major mediator of anti-tumor immune responses; nevertheless, cancer cells use intrigue strategies to alter IFN-γ signaling and avoid elimination. Understanding the immune regulatory mechanisms employed by acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cells upon exposure to IFN-γ is critical for development of immunotherapy and checkpoint blockade therapy approaches. This study aims to explore the influence of myeloid maturation on IFN-γ-induced PD-L1 and PD-L2 expression and on pro-leukemogenic transcription factor STAT3 signaling in AML and MDS. Stimulation of myeloid blasts’ maturation by all-trans retinoic acid (ATRA) or 1α,25-dihydroxyvitamin D3 (vitamin D) increased the CD11b+ fraction that expressed PD-1 ligands in response to IFN-γ. Intriguingly, STAT3 pathway was potently induced by IFN-γ and strengthened upon prolonged exposure. Nonetheless, STAT3-mediated atypical IFN-γ signaling appeared as a negligible factor for PD-L1 and PD-L2 expression. These negative influences of IFN-γ could be alleviated by a small-molecule inhibitor of STAT3, stattic, which also inhibited the upregulation of PD-L1. In conclusion, induction of myeloid maturation enhances the responsiveness of AML and MDS cells to IFN-γ. However, these malignant myeloid cells can exploit both STAT3 pathway and PD-1 ligands to survive IFN-γ-mediated immunity and maintain secondary immune resistance.

29 December 2014 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
NTNihan Turhan
Nihan Turhan
GEGunes Esendagli
Gunes Esendagli
OOOzgur Ozkayar
Ozgur Ozkayar
GTGurcan Tunali
Gurcan Tunali
CSCenk Sokmensuer
Cenk Sokmensuer
OAOsman Abbasoglu
Osman Abbasoglu

3 April 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GTGürcan Tunalı
Gürcan Tunalı
MBMarta Rúbies Bedós
Marta Rúbies Bedós
DNDivya Nagarajan
Divya Nagarajan
PFPatrik Fridh
Patrik Fridh
IPIrineos Papakyriacou
Irineos Papakyriacou
YMYumeng Mao
Yumeng Mao
Inflammatory mediators released by cancer cells promote the induction of immune suppression and tolerance in myeloid cells. Interleukin-1 receptor-associated kinase-3 (IRAK3) is a pseudokinase that inhibits IL-1/TLR signaling but its role in patients treated with immune checkpoint blockade (ICB) therapy remains unclear. Using RNAseq data from the IMvigor210 trial, we found that tumors with high IRAK3 expressions showed enriched anti-inflammatory pathways and worse clinical response to ICB therapy. Upon IRAK3 protein deletion with CRISPR/Cas9, primary human monocytes displayed altered global protein expression and phosphorylation in quantitative proteomics and released more pro-inflammatory cytokines in response to stimulation. Bone-marrow derived macrophages from an IRAK3 CRISPR knockout (KO) mouse model demonstrated a pro-inflammatory phenotype and enhanced sensitivity to TLR agonists, compared to wild-type cells. IRAK3 deficiency delayed the growth of carcinogen-induced and oncogene-driven murine cancer cells and induced enhanced activation in myeloid cells and T cells. Upon ICB treatment, IRAK3 KO mice showed enrichment of TCF1+PD-1+ stem-like memory CD8+ T cells and resulted in superior growth inhibition of immunologically cold tumors in vivo. Altogether, our study demonstrated a novel cancer-driven immune tolerance program controlled by IRAK3 in humans and mice and proposed its suitability as an immunotherapy target.

10 November 2015 in Molecular Immunology
Verified
Journal Article
Closed access
PSParisa Sarmadi
Parisa Sarmadi
GTGurcan Tunali
Gurcan Tunali
GEGuldal Esendagli-Yilmaz
Guldal Esendagli-Yilmaz
KYKerim Bora Yilmaz
Kerim Bora Yilmaz
GEGunes Esendagli
Gunes Esendagli